908 Devices (MASS)
(Delayed Data from NSDQ)
$5.32 USD
-0.02 (-0.37%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $5.33 +0.01 (0.19%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MASS 5.32 -0.02(-0.37%)
Will MASS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MASS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MASS
Wall Street Analysts Predict a 133.69% Upside in 908 Devices (MASS): Here's What You Should Know
908 Devices (MASS) Loses -9.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
MASS: What are Zacks experts saying now?
Zacks Private Portfolio Services
908 Devices Inc. (MASS) Reports Q1 Loss, Tops Revenue Estimates
IQVIA Holdings (IQV) Reports Next Week: Wall Street Expects Earnings Growth
Intuitive Surgical, Inc. (ISRG) Q1 Earnings and Revenues Top Estimates
Other News for MASS
908 Devices Appoints Michele M. Leonhart, Former Administrator of the United States Drug Enforcement Administration (DEA), to Its Board of Directors
908 Devices appoints Leonhart to Board of Directors
908 Devices Enhances XplorIR Portable Analyzer to Simultaneously Identify and Quantify Hazardous Gases and Vapors
908 Devices announce enhanced qualification package for XplorIR
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), 908 Devices (MASS) and Nurix Therapeutics (NRIX)